Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sosei's AD 337 misses Phase II endpoint

Sosei (Tokyo:4565) said oral AD 337 missed the primary endpoint of significantly

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE